{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:57:41Z","timestamp":1782975461671,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transarterial embolization (TAE) constitutes the gold standard for the treatment of hepatocellular carcinoma. The effect of combination of TAE and peglated-H1\/HGFK1 nanoparticles was explored on hepatocellular carcinoma. MTT and Annexin V-FITC were used to determine the cell viability and apoptosis of HepG2, ml-1, LO2, and VX2 cells after the treatment of HGFK1. Next, the orthotopic rabbit was selected to establish the in situ models of VX2 hepatocellular carcinoma. Nanoparticles were synthesized with peglated-PH1 and used to deliver HGFK1 overexpressing plasmids. MRI was performed to monitor tumor volume after being treated with TAE. The protein expression levels of CD31, CD90, and Ki67 were determined by immunohistochemistry. H&amp;E and TUNEL staining were used to determine the necrosis and apoptosis in vivo. HGFK1 significantly inhibited the proliferation and increased the apoptosis of HepG2 and ml-1 cells (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). MRI on 14\u00a0days after modeling suggested that the tumor showed ring enhancement. MRI on 7\u00a0days and 14\u00a0days after interventional therapy showed that tumor volume was significantly inhibited after the treatment with TAE and HGFK1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The immunohistochemical results 7\u00a0days after interventional therapy indicated that the expressions of CD31, CD90, and Ki67 were significantly lower after treatment with TAE and HGFK1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). TAE and HGFK1 all extended the survival period of rabbits (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). PH1\/HGFK1 nanoparticle is an innovative and effective embolic agent, which could limit angiogenesis post-TAE treatment. The combination of TAE with PH1\/HGFK1 is a promising strategy and might alter the way that surgeons manage hepatocellular carcinoma (HCC).<\/jats:p>","DOI":"10.1007\/s12010-022-04153-7","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T09:02:56Z","timestamp":1662973376000},"page":"505-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of Peglated-H1\/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"195","author":[{"given":"Dazhi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqi","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"4153_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","volume":"152","author":"D Sia","year":"2017","unstructured":"Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology, 152, 745\u2013761.","journal-title":"Gastroenterology"},{"key":"4153_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018). Molecular therapies and precision medicine for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 15, 599\u2013616.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"4153_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud, G. N., & Li, W. (2015). HIF-1alpha pathway: Role, regulation, and intervention for cancer therapy. Acta Pharmaceutica Sinica B, 5, 378\u2013389.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"4153_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/cgt.2012.38","volume":"19","author":"Y Yao","year":"2012","unstructured":"Yao, Y., Fang, Z. P., Chen, H., Yue, L., Min, D. L., Tang, L. N., Yu, W. X., Kung, H. F., Lin, M. C., & Shen, Z. (2012). HGFK1 inhibits bone metastasis in breast cancer through the TAK1\/p38 MAPK signaling pathway. Cancer Gene Therapy, 19, 601\u2013608.","journal-title":"Cancer Gene Therapy"},{"key":"4153_CR5","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1158\/1535-7163.MCT-08-0366","volume":"7","author":"B Nie","year":"2008","unstructured":"Nie, B., Shen, Z., Wen, J. B., Wong, O. G., Hsueh, W. D., Huo, L. F., Kung, H. F., Jiang, B., & Lin, M. C. (2008). AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Molecular Cancer Therapeutics, 7, 2855\u20132865.","journal-title":"Molecular Cancer Therapeutics"},{"key":"4153_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/0008-5472.CAN-07-2081","volume":"68","author":"Z Shen","year":"2008","unstructured":"Shen, Z., Yang, Z. F., Gao, Y., Li, J. C., Chen, H. X., Liu, C. C., Poon, R. T., Fan, S. T., Luk, J. M., Sze, K. H., Li, T. P., Gan, R. B., He, M. L., Kung, H. F., & Lin, M. C. (2008). The kringle 1 domain of hepatocyte growth factor has anti-angiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Research, 68, 404\u2013414.","journal-title":"Cancer Research"},{"key":"4153_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbrc.2018.11.111","volume":"508","author":"P Sun","year":"2019","unstructured":"Sun, P., & Liu, Z. (2019). Overexpressing kringle 1 domain of hepatocyte growth factor with adeno-associated virus inhibits the pathological retinal neovascularization in an oxygen-induced retinopathy mouse model. Biochemical and Biophysical Research Communications, 508, 130\u2013137.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"4153_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.exer.2012.10.004","volume":"105","author":"Q Lu","year":"2012","unstructured":"Lu, Q., Zhang, L., Shen, X., Zhu, Y., Zhang, Q., Zhou, Q., Gan, R., Zhang, H., Zhong, Y., & Xie, B. (2012). A novel and effective human hepatocyte growth factor kringle 1 domain inhibits ocular neovascularization. Experimental Eye Research, 105, 15\u201320.","journal-title":"Experimental Eye Research"},{"key":"4153_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/bjc.2017.461","volume":"118","author":"W Zhang","year":"2018","unstructured":"Zhang, W., Duan, R., Zhang, J., Cheung, W. K. C., Gao, X., Zhang, R., Zhang, Q., Wei, M., Wang, G., Zhang, Q., Mei, P. J., Chen, H. L., Kung, H., Lin, M. C., Shen, Z., Zheng, J., Zhang, L., & Yao, H. (2018). H1\/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma. British Journal of Cancer, 118, 522\u2013533.","journal-title":"British Journal of Cancer"},{"issue":"11","key":"4153_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.114.302331","volume":"114","author":"S Zacchigna","year":"2014","unstructured":"Zacchigna, S., Zentilin, L., & Giacca, M. (2014). Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circulation Research, 114(11), 1827\u20131846.","journal-title":"Circulation Research"},{"key":"4153_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","volume":"24","author":"N Maheshri","year":"2006","unstructured":"Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006). Directed evolution of adeno- associated virus yields enhanced gene delivery vectors. Nature Biotechnology, 24, 198\u2013204.","journal-title":"Nature Biotechnology"},{"key":"4153_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jconrel.2009.07.009","volume":"140","author":"R Deng","year":"2009","unstructured":"Deng, R., Yue, Y., Jin, F., Chen, Y., Kung, H. F., Lin, M. C., & Wu, C. (2009). Revisit the complexation of PEI and DNA - How to make low cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? Journal of Controlled Release, 140, 40\u201346.","journal-title":"Journal of Controlled Release"},{"key":"4153_CR13","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.biomaterials.2009.06.051","volume":"30","author":"H Yao","year":"2009","unstructured":"Yao, H., Ng, S. S., Tucker, W. O., Tsang, Y. K., Man, K., Wang, X. M., Chow, B. K., Kung, H. F., Tang, G. P., & Lin, M. C. (2009). The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. Biomaterials, 30, 5793\u20135803.","journal-title":"Biomaterials"},{"key":"4153_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13046-019-1348-z","volume":"38","author":"X Gao","year":"2019","unstructured":"Gao, X., Jiang, P., Zhang, Q., Liu, Q., Jiang, S., Liu, L., Guo, M., Cheng, Q., Zheng, J., & Yao, H. (2019). Peglated-H1\/pHGFK1 nanoparticles enhance antitumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. Journal of Experimental & Clinical Cancer Research, 38, 362.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"4153_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000343872","volume":"3","author":"JL Raoul","year":"2014","unstructured":"Raoul, J. L., Park, J. W., Kang, Y. K., Finn, R. S., Kim, J. S., Yeo, W., Polite, B. N., Chao, Y., Walters, I., Baudelet, C., & Lencioni, R. (2014). Using modified RECIST and alpha-fetoprotein levels to assess treatment benefit in hepatocellular carcinoma. Liver Cancer, 3, 439\u2013450.","journal-title":"Liver Cancer"},{"key":"4153_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/bjc.2017.121","volume":"116","author":"BR Dickie","year":"2017","unstructured":"Dickie, B. R., Rose, C. J., Kershaw, L. E., Withey, S. B., Carrington, B. M., Davidson, S. E., Hutchison, G., & West, C. M. L. (2017). The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K(trans) in cervical cancer is explained by plasma flow rather than vessel permeability. British Journal of Cancer, 116, 1436\u20131443.","journal-title":"British Journal of Cancer"},{"key":"4153_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.15252\/emmm.201404396","volume":"7","author":"S Meidhof","year":"2015","unstructured":"Meidhof, S., Brabletz, S., Lehmann, W., Preca, B. T., Mock, K., Ruh, M., Sch\u00fcler, J., Berthold, M., Weber, A., Burk, U., L\u00fcbbert, M., Puhr, M., Culig, Z., Wellner, U., Keck, T., Bronsert, P., K\u00fcsters, S., Hopt, U. T., Stemmler, M. P., & Brabletz, T. (2015). ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Molecular Medicine, 7, 831\u2013847.","journal-title":"EMBO Molecular Medicine"},{"key":"4153_CR18","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1158\/0008-5472.CAN-17-2445","volume":"78","author":"BY Cheng","year":"2018","unstructured":"Cheng, B. Y., Lau, E. Y., Leung, H. W., Leung, C. O., Ho, N. P., Gurung, S., Cheng, L. K., Lin, C. H., Lo, R. C., Ma, S., Ng, I. O., & Lee, T. K. (2018). IRAK1 augments cancer stemness and drug resistance via the AP-1\/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Research, 78, 2332\u20132342.","journal-title":"Cancer Research"},{"issue":"2","key":"4153_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/v14020428","volume":"14","author":"YT Lin","year":"2022","unstructured":"Lin, Y. T., Jeng, L. B., Su, I. J., & Teng, C. F. (2022). Approaches for detection of hepatitis B virus Pre-S gene deletions and Pre-S deleted proteins and their application in prediction of higher risk of hepatocellular carcinoma development and recurrence. Viruses, 14(2), 428.","journal-title":"Viruses"},{"key":"4153_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","volume":"1018","author":"Y Xie","year":"2017","unstructured":"Xie, Y. (2017). Hepatitis B virus-associated hepatocellular carcinoma. Advances in Experimental Medicine and Biology, 1018, 11\u201321.","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"3","key":"4153_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5582\/bst.2021.01083","volume":"15","author":"D Liu","year":"2021","unstructured":"Liu, D., & Song, T. (2021). Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. BioScience Trends, 15(3), 142\u2013147.","journal-title":"BioScience Trends"},{"issue":"1","key":"4153_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R., & Zhou, J. (2020). Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 5(1), 146.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"4153_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/13645706.2018.1432489","volume":"27","author":"D Gnutzmann","year":"2018","unstructured":"Gnutzmann, D., Kortes, N., Sumkauskaite, M., Schmitz, A., Weiss, K. H., & Radeleff, B. (2018). Transvascular therapy of hepatocellular carcinoma (HCC), status and developments. Minimally Invasive Therapy & Allied Technologies, 27, 69\u201380.","journal-title":"Minimally Invasive Therapy & Allied Technologies"},{"key":"4153_CR24","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1148\/rg.25si055508","volume":"25","author":"HC Kim","year":"2005","unstructured":"Kim, H. C., Chung, J. W., Lee, W., Jae, H. J., & Park, J. H. (2005). Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics, 25, S25\u2013S39.","journal-title":"Radiographics"},{"issue":"1","key":"4153_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1148\/radiology.219.1.r01mr28147","volume":"219","author":"M Nakai","year":"2001","unstructured":"Nakai, M., Sato, M., Kawai, N., Minamiguchi, H., Masuda, M., Tanihata, H., Takeuchi, T., Terada, M., & Kishi, K. (2001). Hepatocellular carcinoma: Involvement of the internal mammary artery. Radiology, 219(1), 147\u2013152.","journal-title":"Radiology"},{"issue":"12","key":"4153_CR26","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1007\/s10620-013-2872-x","volume":"58","author":"O Abdel-Rahman","year":"2013","unstructured":"Abdel-Rahman, O., & Elsayed, Z. A. (2013). Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: A systematic review of the literature. Digestive Diseases and Sciences, 58(12), 3389\u20133396.","journal-title":"Digestive Diseases and Sciences"},{"issue":"11","key":"4153_CR27","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/0008-5472.CAN-12-4039","volume":"73","author":"C Boccaccio","year":"2013","unstructured":"Boccaccio, C., & Comoglio, P. M. (2013). The MET oncogene in glioblastoma stem cells: Implications as a diagnostic marker and a therapeutic target. Cancer Research, 73(11), 3193\u20133199.","journal-title":"Cancer Research"},{"issue":"2","key":"4153_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/cas.14262","volume":"111","author":"R Zhang","year":"2020","unstructured":"Zhang, R., Gao, X., Zuo, J., Hu, B., Yang, J., Zhao, J., & Chen, J. (2020). STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway. Cancer Science, 111(2), 406\u2013417.","journal-title":"Cancer Science"},{"issue":"1","key":"4153_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/TP.0000000000001936","volume":"102","author":"D Sneiders","year":"2018","unstructured":"Sneiders, D., Houwen, T., Pengel, L. H. M., Polak, W. G., Dor, F. J. M. F., & Hartog, H. (2018). Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation. Transplantation, 102(1), 88\u201396.","journal-title":"Transplantation"},{"key":"4153_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12029-017-0014-y","volume":"50","author":"SY Mohamed","year":"2019","unstructured":"Mohamed, S. Y., Mohammed, H. L., Ibrahim, H. M., Mohamed, E. M., & Salah, M. (2019). Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. Journal of Gastrointestinal Cancer, 50, 23\u201334.","journal-title":"Journal of Gastrointestinal Cancer"},{"key":"4153_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.yexcr.2015.09.007","volume":"339","author":"G Musumeci","year":"2015","unstructured":"Musumeci, G., Castorina, A., Magro, G., Cardile, V., Castorina, S., & Ribatti, D. (2015). Enhanced expression of CD31\/platelet endothelial cell adhesion molecule 1 (PECAM1) correlates with hypoxia-inducible factor-1 alpha (HIF-1alpha) in human glioblastoma multiforme. Experimental Cell Research, 339, 407\u2013416.","journal-title":"Experimental Cell Research"},{"key":"4153_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev.cellbio.22.010305.104154","volume":"23","author":"NA Lobo","year":"2007","unstructured":"Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007). The biology of cancer stem cells. Annual Review of Cell and Developmental Biology, 23, 675\u2013699.","journal-title":"Annual Review of Cell and Developmental Biology"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-022-04153-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-022-04153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T16:11:27Z","timestamp":1673626287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-022-04153-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4153"],"URL":"https:\/\/doi.org\/10.1007\/s12010-022-04153-7","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"28 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by the ethics committee of Jinling Hospital affiliated with Nanjing University (no. 2020DZGKJDWLS-00174).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Yes. All authors agreed to participate in this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Yes. All authors have approved the last version of the manuscript for its submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}